Debra Schultz
Acute Care · Paw Paw, MINPI 1124194279
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 97.2% of the total across 198 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 22 manufacturers reported payments, led by GSK at 28.1% of the total. Reporting peaked in 2021 at $1,297 and has fallen 62.3% since, to $490 in 2025. Among acute care clinicians in MI with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 198 payments — averaging $14.28 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- GSK$794
- AstraZeneca$409
- Boehringer Ingelheim$364
- Mylan Specialty L.p.$240
- Regeneron Healthcare Solutions, Inc.$176
- Jazz Pharmaceuticals Inc.$158
- plus $687 from 16 others
What the payments were for
- Food & beverage$2,74897%
- Education$803%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| GSK | 68 | $794 |
| AstraZeneca | 23 | $409 |
| Boehringer Ingelheim | 20 | $364 |
| Mylan Specialty L.p. | 14 | $240 |
| Regeneron Healthcare Solutions, Inc. | 5 | $176 |
| Jazz Pharmaceuticals Inc. | 33 | $158 |
| Actelion Pharmaceuticals US, Inc. | 5 | $117 |
| Takeda Pharmaceuticals U.S.A., Inc. | 4 | $85 |
| Harmony Biosciences LLC | 2 | $62 |
| Philips North America LLC | 3 | $53 |
| Insmed, Inc. | 3 | $53 |
| Viatris Specialty LLC | 2 | $51 |
| Genentech USA, Inc. | 4 | $45 |
| Grifols USA, LLC | 2 | $38 |
| Nabriva Therapeutics, PLC | 2 | $37 |
| Electromed, Inc. | 2 | $35 |
| Inogen, Inc. | 1 | $27 |
| Pulmonx Corporation | 1 | $23 |
| Baxter Healthcare | 1 | $21 |
| Verona Pharma, Inc. | 1 | $14 |
| Johnson & Johnson | 1 | $14 |
| Sanofi | 1 | $13 |
How this compares
$2,827 in reported general payments places this provider in the 90th percentile of 567 acute care providers in Michigan.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 918 | $710,443 |
| Dupixent PenDupilumab | 69 | $270,035 |
| NucalaMepolizumab | 67 | $257,747 |
| AdempasRiociguat | 11 | $154,306 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 166 | $116,427 |
| EsbrietPirfenidone | 11 | $114,379 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 108 | $63,105 |
| Dupixent SyringeDupilumab | 17 | $59,416 |
| Breo ElliptaFluticasone/Vilanterol | 104 | $59,142 |
| Combivent RespimatIpratropium/Albuterol Sulfate | 76 | $50,758 |
| TezspireTezepelumab-Ekko | 12 | $50,734 |
| Spiriva RespimatTiotropium Bromide | 67 | $45,318 |
| SymbicortBudesonide/Formoterol Fumarate | 103 | $29,113 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 41 | $29,076 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 675 | $23,739 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta, Nucala, Anoro Ellipta, Breo Ellipta, Incruse Ellipta | $794 | $1,102,3831,225 claims |
| AstraZenecaBreztri Aerosphere, Tezspire, Symbicort, Bevespi Aerosphere, Pulmicort Flexhaler | $409 | $206,413311 claims |
| Boehringer IngelheimCombivent Respimat, Spiriva Respimat, Stiolto Respimat | $364 | $125,153184 claims |
| Genentech USA, Inc.Esbriet | $45 | $114,37911 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 567 acute care providers in Michigan.
Other acute care in Paw Paw
- Janet WymanDetroit$103K
- Stephanie Mellon ReppenDetroit$57K
- Ashley WozniakLivonia$26K
- Julia BriggsBirch Run$16K
- Candise LovePort Huron$14K
- Janette GuertinPort Huron$14K
- Gregory AliNovi$13K
- Andrew PalmerLansing$9K
- Angela BrennanDearborn Heights$7K
- Jennifer RutzenLansing$7K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.